• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides a pharmaceutical composition which is substantially free of unpleasant tastes and orally administrable which comprises: (a) an active medicament, (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C., (c) an outer coating layer comprising at least a polymeric substance.
    公开号:US20010000471A1
    申请号:US09/738,333
    申请日:2000-12-15
    公开日:2001-04-26
    发明作者:Robert Shen；Gerald Walter
    申请人:Shen Robert W.；Walter Gerald A.；
    IPC主号:A61K9-1617
    专利说明:
    [1] 1. This application claims the benefit of U.S. application Ser. No. 09/139,449, filed Aug. 25, 1998. FIELD OF THE INVENTION
    [2] 2. The present invention relates to an orally administrable pharmaceutical composition. More specifically, the present invention relates to a pharmaceutical composition comprising an active medicament with two coating layers which is substantially free of unpleasant tastes. BACKGROUND OF THE INVENTION
    [3] 3. Dimenhydrinate is a well-known therapeutic agent for the prevention or treatment of motion sickness. Like many drugs, however, in particular drugs containing amine or amido groups, it has a strong bitter taste. Without proper taste masking, dimenhydrinate and such drugs cannot be adapted into acceptable orally administrable forms, especially in the form of chewable tablets. Current taste masking techniques, including simple polymer coating of the drug substance, have not been entirely satisfactory for dimenhydrinate to achieve the desired degree of taste masking due to its appreciable solubility in both aqueous medium and various organic solvents. Therefore, solvents used in conventional coating processes often partially dissolve the drug and expose the drug substance on the surface of the preparation.
    [4] 4. Recognizing the problems, the present invention is directed toward a taste-masking coating preparation for active medicaments which have the solubility profile as dimenhydrinate, i.e. the ability to dissolve in both organic solutions or aqueous medium in an appreciable extent. We have found that by using two appropriate coating layers such active medicaments can be substantially free from the unpleasant tastes. INFORMATION DISCLOSURE
    [5] 5. Abstract of Japanese Patent No. 116652 discloses the production of wax coated granulated pharmaceutical products using paraffins, beeswax, higher alcohols and/or fatty acid (esters).
    [6] 6. The International Publication No. WO 94/08576 discloses a composition which is substantially free of the bitter taste associated with ranitidine and comprises a) a dispersion of lipid coated particles of ranitidine or a physiologically acceptable salt thereof in a non-aqueous vehicle, b) particles comprising ranitidine or a physiologically acceptable salt thereof incorporated into a core and coated with a lipid coating, and c) lipid coated particles of a form of ranitidine which is poorly soluble in water.
    [7] 7. European Patent Application No. 0 409 254 A1 discloses a rapid-releasing oral particle pharmaceutical preparation with its unpleasant taste masked comprising a core and a film layer coating the core, the core at least containing a drug having an unpleasant taste and a water swelling agent, and the film layer at least containing ethylcellulose and a water-soluble substance. SUMMARY OF THE INVENTION
    [8] 8. One object of the present invention is to provide a pharmaceutical composition comprising an active medicament for oral administration, which is substantially free of unpleasant tastes associated with the active medicament.
    [9] 9. A specific object of the present invention is to provide a pharmaceutical composition for oral administration which comprises an active medicament that is capable of being dissolved in both organic solutions or aqueous medium in an appreciable extent.
    [10] 10. A further object of the present invention is to provide a pharmaceutical composition comprising an active medicament for oral administration in a form of chewable tablet, which has good taste, good appearance and suitable hardness.
    [11] 11. The objects of the present invention have been accomplished in that the present invention provides a pharmaceutical composition that is substantially free of unpleasant tastes and orally administrable which comprises:
    [12] 12. (a) an active medicament,
    [13] 13. (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C.,
    [14] 14. (c) an outer coating layer comprising at least a polymeric substance. DETAILED DESCRIPTION OF THE INVENTION
    [15] 15. According to one aspect, the present invention provides a pharmaceutical composition which is substantially free of its bitter taste.
    [16] 16. The present invention is formed from an active medicament having an inner coating layer and an outer coating layer. The active medicaments are of the ability to dissolve in both organic solutions or aqueous medium. However, while the composition of the present invention for such medicaments is its most important utility, they are applicable to all pharmaceutically active agents as well.
    [17] 17. A suitable composition according to the present invention comprises an active medicament having an inner coating layer to form an inner core wherein the active medicament is in an amount of from about 5% to about 65% and the inner coating layer is in an amount of from about 95% to about 35% by weight of the entire inner core of the composition. The preferred inner core composition comprises an active medicament in an amount of about 50% and an inner coating layer in an amount of about 50% by weight of the entire inner core of the composition. The amount of active medicament in the composition is adjusted widely depending on the particular active medicament being used and the required concentration.
    [18] 18. The oil substance useful in forming the inner layer of the composition includes a broad spectrum of pharmaceutically acceptable water-immiscible materials having a melting point at the range of from about 50° C. to about 100° C. such as hydrogenated vegetable or animal oil. For example, the oil substance can be hydrogenated or partially hydrogenated soybean oil, avocado oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, flavored oils, water insoluble vitamins, or polyethlyene glycol polymer having a melting point at least above 50° C., and mixtures thereof. The preferred oil for the inner coating layer is hydrogenated soybean oil.
    [19] 19. The pharmaceutical composition of the present invention further comprises a polymer substance as an outer coating layer. Suitable pharmaceutically acceptable polymer substance for use in the outer coating layer includes cellulose based polymers such as alkylcelluloses, for example, methylcellulose, ethylcellulose or propylcellulose; hydroxyalkylcelluloses, for example, hydroxypropylcellulose or hydroxypropylmethylcellulose; and other cellulose based polymers, for example, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate; and methacrylic acid copolymers; aminoalkyl methacrylate copolymers; methacrylic ester copolymers; glycerate triacetate; triethylcitrate; acetyl triethylcitrate; tributyl citrate; acetyl tributyl citrate; diethyl phthalate; dibutyl phthalate; or dibutyl sebacate. Particularly preferred polymeric substance is ethylcellulose, which may be any of the pharmaceutically acceptable ones, for example one having an ethoxyl content of 46.5 to 51% and having a viscosity of 4 to 100 cps. The outer coating layer may contain, in addition to polymeric substance, other pharmaceutical components such as suitable plastercizer, for example, propylene glycol or polyethlyene glycol polymer 400; or solvents, for example, ethanol, isopropyl alcohol, acetone or water. In general, the polymer substance is in an amount of from about 4% to 90% by weight of the total composition. The inner core is in an amount of from about 90% to about 4% by weight of the total composition and the other components are in the amount of from about 1% to about 40%. In a preferred composition of the present invention, the polymer substance is in an amount of from about 20% to about 40%, the inner core is in an amount from about 40% to about 70%, and the other composition is in an amount of from about 1% to about 5%.
    [20] 20. If desired, the composition of the present invention may further comprise conventional pharmaceutical acceptable additives such as coloring agents, flavoring agents, fragrances, preserving agents, stabilizers, anti-oxidant and/or thickening agents.
    [21] 21. The compositions according to the present invention may take the form of granules, tablets, pellets, pills, powders or capsules for oral administration. One important feature of the present invention is that the oil substance employed in the inner coating layer provides great flexibility; thereby the composition of the present invention is capable of being bent or flexed without damage during the tablet compressing process, and the medicine inside the oil coated beadlets will not leak out after chewing. As such, a chewable tablet is the particularly preferred dosage form of the present invention, which may be obtained by compressing the granules with a suitable chewable base such as sucrose, sorbitol, glucose, xylitol, mannitol or a mixture thereof.
    [22] 22. The composition of the present invention may be prepared by known manufacturing techniques, for example, using a hot melt coating method to form an inner coating layer and then spray a suitable polymer solution on the inner core. The present invention will be better understood in connection with the following preparations and examples, which are intended as an illustration of and not a limitation upon the scope of the invention. Without further elaboration, it is believed that one skilled in the art can, using the preceding description and the information provided in the examples below, practice the present invention to its fullest extent. PREPARATION 1 Oil Coating the Inner Layer
    [23] 23. Dimenhydrinate 5 Kg Stearine Flake #17 (hydrogenated soybean oil) 5 Kg
    [24] 24. To a stainless steel container, add Stearine Flakes and place the container on a hot plate. Apply heat to the hot plate to melt the flakes and maintain the batch temperature to about 80-85° C. To a Glatt GPCG 5, insulate the air supply unit (including the nozzle, nozzle wand and atomization air line). Atomization air is preheated to above 100° C. by using an air heater. Dimenhydrinate is added to the Glatt product container. Turn the turbine on by using cold air when the spraying system is hot. Spray the melted soybean oil on the dimenhydrinate and maintain the product temperature at about 48° C. by monitoring the spray rate until all of the soybean oil is used. Cool the batch to about 35° C. and then remove the product from Glatt product container. The product is screened through a #16 mesh screen. PREPARATION 2 Polymer Coating the Outer Layer
    [25] 25. Stearine coated Dimenhydrinate 4 Kg (50% active ingredient) Ethylcellulose NF 4 cps 2 Kg Propylene Glycol USP 220 g Isopropyl Alcohol 14 Kg Acetone 6 Kg
    [26] 26. To a suitable container add Isopropyl Alcohol, Acetone and the Propylene Glycol. While mixing slowly, add the Ethylcellulose into the above solvents and mix them until all of Ethylcellulose is dissolved. To the Glatt product container add the Stearine coated Dimenhydrinate. Spray the Ethylcellulose solution on to the batch according to the following parameters: Product temperature: 24-27° C. Exhaust temperature: 26° C. Inlet temperature: 40° C. Atomization air: 3 bar Spray rate: 135 g/minute
    [27] 27. The twice coated product is screened through a #16 mesh screen. PREPARATION 3 Chewable Tablet (Grape Flavored)
    [28] 28. Formula for 1,000 tabletsTwice coated Dimenhydrinate 152.0 g (32.9% active ingredient) Manitol USP 248.7 g Sorbitol NF 248.7 g Malic Acid NF 10.5 g Aspartame NF 7.0 g Grape Flavor (spray dried, WL-261 20.0 g FDC Red Lake #40 2.0 g FDC Blue Lake #1 0.6 g Magnesium Stearate NF 10.5 g
    [29] 29. Add the above ingredients (without the Magnesium Stearate) into a Patterson-Kelley blender and mix for 30 minutes. Add the Magnesium Stearate and mix for 3 minutes. Compress the material into tablets using a tablet press with the weight of the tablets at 700 mg/tablet and tablet harness at 6-9 Strong Cobb Units.
    [30] 30. Tablet hardness: 6-9 SCU
    [31] 31. Friability: 0.2%
    [32] 32. Taste: excellent taste with good color appearance EXAMPLE 1
    [33] 33. A. Dimenhydrinate USP   50% Hydrogenated soybean oil   50% B. Ethylcellulose NF 4 cps 32.15% Oil coated Dimenhydrinate 64.31% Propylene Glycol  3.53%
    权利要求:
    Claims (14)
    [1" id="US-20010000471-A1-CLM-00001] 1. A pharmaceutical composition which comprises:
    (a) an active medicament,
    (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C., and
    (c) an outer coating layer comprising at least a polymer substance, wherein the active medicament and the inner coating layer form an inner core.
    [2" id="US-20010000471-A1-CLM-00002] 2. A composition according to
    claim 1 wherein the active medicament is capable of being dissolved in both organic solutions or aqueous medium.
    [3" id="US-20010000471-A1-CLM-00003] 3. A composition according to
    claim 1 wherein the active medicament is dimenhydrinate.
    [4" id="US-20010000471-A1-CLM-00004] 4. A composition according to
    claim 1 wherein the oil substance is soybean oil, avocado oil, squalene oil, sesame oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, flavored oils, water insoluble vitamins, water insoluble vitamins, polyethlyene glycol polymer having a melting point at least above 50° C. or mixtures thereof.
    [5" id="US-20010000471-A1-CLM-00005] 5. A composition according to
    claim 1 wherein the active medicament is in an amount of from about 5% to about 65% by weight of the total inner core.
    [6" id="US-20010000471-A1-CLM-00006] 6. A composition according
    claim 1 wherein the active medicament is in an amount of about 50% by weight of the total inner core.
    [7" id="US-20010000471-A1-CLM-00007] 7. A composition according to
    claim 1 wherein the oil substance is in an amount of from about 95% to about 35% by weight of the total inner core.
    [8" id="US-20010000471-A1-CLM-00008] 8. A composition according to
    claim 1 wherein the oil substance is in an amount of about 50% by weight of the total inner core.
    [9" id="US-20010000471-A1-CLM-00009] 9. A composition according to
    claim 1 wherein the polymer substance is methylcellulose, ethylcellulose, propylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, methacrylic acid copolymers, aminoalkyl methacrylate copolymers, methacrylic ester copolymers, glycerate triacetate, triethylcitrate, acetyl triethylcitrate, tributyl citrate, acetyl tributyl citrate, diethyl phthalate, dibutyl phthalate or dibutyl sebacate.
    [10" id="US-20010000471-A1-CLM-00010] 10. A composition according to
    claim 1 wherein the oil substance is in an amount of about 4% to about 90% by weight of the total composition.
    [11" id="US-20010000471-A1-CLM-00011] 11. A composition according to
    claim 1 wherein the inner core is in an amount of about 90% to about 4% by weight of the total composition.
    [12" id="US-20010000471-A1-CLM-00012] 12. A pharmaceutical composition comprising:
    (a) an active medicament comprising dimenhydrinate in an amount of about from 20% to about 40%,
    (b) an inner coating layer comprising soybean oil in an amount of about from about 20% to about 40%, and
    (c) an outer coating layer comprising at least ethylcellulose.
    [13" id="US-20010000471-A1-CLM-00013] 13. A pharmaceutical composition according to
    claim 1 which is in a form of chewable tablet for oral administration.
    [14" id="US-20010000471-A1-CLM-00014] 14. A pharmaceutical composition according to
    claim 12 which is in a form of chewable tablet for oral administration.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6939560B2|2005-09-06|Pharmaceutical composition having two coating layers
    EP1166777B1|2008-08-13|Taste masked pharmaceutical particles
    JP3350559B2|2002-11-25|Mechanically stable and easily disintegrable tablets made from preformed microparticles containing the active ingredient
    EP0523847B1|1996-04-24|Taste mask coating for preparation of chewable pharmaceutical tablets
    EP0524180B1|1995-04-26|Taste masking of ibuprofen by fluid bed coating
    KR101157220B1|2012-07-09|Gastroresistant pharmaceutical formulations containing rifaximin
    US20060204587A1|2006-09-14|Use of film coating as taste-masking coating of oral dosage forms
    JP2004277426A|2004-10-07|Composition containing sucralose
    KR100660072B1|2006-12-22|Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
    JPH06316536A|1994-11-15|Taste-masking and sustained-release film for medicine
    US20030064107A1|2003-04-03|Taste masked pharmaceutical liquid formulations
    CN101283967B|2015-02-25|Basis particles, method for manufacturing same,and orally-disintegrating tablet containing them
    EP3154529B1|2020-07-08|Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
    KR20030081489A|2003-10-17|Utilization of spray-dried powder containing sugar alcohol
    CA2121038C|2002-05-14|Oral preparation for release in lower digestive tracts
    WO2000069420A1|2000-11-23|Pulse-delivery oral compositions
    JP2008525389A|2008-07-17|Novel galenic formulation system for active ingredient transfer, its production method and use
    KR20020069377A|2002-09-04|A process for preparing release controlled granules of quinolone drugs having masked taste and smell
    MXPA00002099A|2001-03-05|A pharmaceutical composition having two coating layers
    MXPA01002821A|2001-12-04|Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
    CZ2001984A3|2001-07-11|Retarded pharmaceutical multicomponent preparations independent on agitation and process of their preparation
    同族专利:
    公开号 | 公开日
    AU9201198A|1999-03-22|
    EP1007009A1|2000-06-14|
    CN1265029A|2000-08-30|
    KR100540715B1|2006-01-10|
    DK1007009T3|2004-11-01|
    DE69825165T2|2005-07-14|
    JP2001514210A|2001-09-11|
    EP1007009B1|2004-07-21|
    CN1150893C|2004-05-26|
    AT271377T|2004-08-15|
    SI1007009T1|2004-12-31|
    PT1007009E|2004-10-29|
    KR20010023384A|2001-03-26|
    AU743154B2|2002-01-17|
    US6228397B1|2001-05-08|
    HK1028880A1|2001-03-09|
    CA2299511C|2007-01-02|
    US6939560B2|2005-09-06|
    ES2226168T3|2005-03-16|
    CA2299511A1|1999-03-11|
    NZ503086A|2002-03-01|
    DE69825165D1|2004-08-26|
    WO1999011245A1|1999-03-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5215755A|1989-08-04|1993-06-01|Mcneil-Ppc, Inc.|Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets|
    US5320855A|1989-08-04|1994-06-14|Mcneil-Ppc, Inc.|Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets|
    US5489436A|1991-06-14|1996-02-06|Mcneil-Ppc, Inc.|Taste mask coatings for preparation of chewable pharmaceutical tablets|
    US5429825A|1992-06-26|1995-07-04|Mcneil-Ppc, Inc.|Rotomelt granulation|
    US6228397B1|1997-08-29|2001-05-08|Pharmacia & Upjohn Company|Pharmaceutical composition having two coating layers|
    US5891476A|1997-12-22|1999-04-06|Reo; Joe P.|Tastemasked pharmaceutical system|US20030108607A1|2001-09-28|2003-06-12|Szymczak Christopher E.|Film forming compositions containing sucralose|
    US6645180B1|2000-09-15|2003-11-11|Thomas Hatch|Single-use syringe|
    US20070259098A1|2001-05-15|2007-11-08|Cynthia Gulian|Method for dip coating dosage forms|
    US20090092739A1|2001-05-15|2009-04-09|Cynthia Gulian|Method of dip-coating dosage forms|US4804548A|1984-10-05|1989-02-14|Warner-Lambert Company|Novel sweetener delivery systems|
    US4828857A|1984-10-05|1989-05-09|Warner-Lambert Company|Novel sweetener delivery systems|
    US4849227A|1986-03-21|1989-07-18|Eurasiam Laboratories, Inc.|Pharmaceutical compositions|
    US4842867A|1986-05-09|1989-06-27|Alza Corporation|Pulsed drug delivery of doxylamine|
    NL8601890A|1986-07-21|1988-02-16|Polynorm Nv|METHOD FOR MANUFACTURING A PANEL|
    JPH0636720B2|1986-11-06|1994-05-18|不二製油株式会社|Soy protein manufacturing method|
    US4808413B1|1987-04-28|1991-09-10|Squibb & Sons Inc||
    US5082669A|1989-07-20|1992-01-21|Dainippon Pharmaceutical Co., Ltd.|Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked|
    ES2085465T3|1989-11-13|1996-06-01|Abraham J Domb|LIPOESFERAS FOR THE CONTROLLED ADMINISTRATION OF SUBSTANCES.|
    IE61651B1|1990-07-04|1994-11-16|Zambon Spa|Programmed release oral solid pharmaceutical dosage form|
    US5380535A|1991-05-28|1995-01-10|Geyer; Robert P.|Chewable drug-delivery compositions and methods for preparing the same|
    DE69227773T2|1991-07-03|1999-05-20|Upjohn Co|TABLETS HIGH IN COLESTIPOLHYDROCHLORIDE|
    JPH08510989A|1992-10-16|1996-11-19|グラクソ、グループ、リミテッド|Ranitidine composition|US6057139A|1995-06-29|2000-05-02|Mcneil-Ppc, Inc.|Preblend of microcrystalline cellulose and lactase for making tablets|
    US8563522B2|1997-07-08|2013-10-22|The Iams Company|Method of maintaining and/or attenuating a decline in quality of life|
    NZ503086A|1997-08-29|2002-03-01|Upjohn Co|An orally administrable pharmaceutical composition comprising an inner core and two outer layers, which render it substantially free of unpleasant tastes|
    US8895064B2|1999-06-14|2014-11-25|Cosmo Technologies Limited|Controlled release and taste masking oral pharmaceutical composition|
    RU2246293C2|1999-06-14|2005-02-20|Космо С.П.А.|Pharmaceutical compositions for oral administration with sustained-releasing active component and masking taste|
    US10154964B2|2011-09-07|2018-12-18|Cosmo Technologies Limited|Controlled release and taste masking oral pharmaceutical composition|
    JP3718398B2|2000-01-11|2005-11-24|信越化学工業株式会社|Film coating agent and oral solid preparation|
    US8168170B2|2002-10-03|2012-05-01|The Procter And Gamble Company|Compositions having an inner core and at least three surrounding layers|
    US8894991B2|2003-12-19|2014-11-25|The Iams Company|Canine probiotic Lactobacilli|
    US8877178B2|2003-12-19|2014-11-04|The Iams Company|Methods of use of probiotic bifidobacteria for companion animals|
    US20050152884A1|2003-12-19|2005-07-14|The Procter & Gamble Company|Canine probiotic Bifidobacteria globosum|
    US7785635B1|2003-12-19|2010-08-31|The Procter & Gamble Company|Methods of use of probiotic lactobacilli for companion animals|
    US20050158294A1|2003-12-19|2005-07-21|The Procter & Gamble Company|Canine probiotic Bifidobacteria pseudolongum|
    GB0330009D0|2003-12-24|2004-01-28|Ferrosan As|Probiotic tablet formulations|
    JP2008534591A|2005-03-29|2008-08-28|マクニール−ピーピーシー・インコーポレーテツド|Composition having a hydrophilic drug in a hydrophobic solvent|
    ES2607988T3|2005-05-31|2017-04-05|Iams Europe B.V.|Feline probiotic bifidobacteria|
    DK1880001T3|2005-05-31|2011-09-12|Iams Company|Feline probiotic lactobacilli|
    US20070098746A1|2005-11-02|2007-05-03|Nichols William M|Multi-layered coating technology for taste masking|
    US20070184111A1|2006-02-03|2007-08-09|Pharmavite Llc|Hybrid tablet|
    US20080131467A1|2006-11-30|2008-06-05|Dennis Nelson|Film-coated solid dosage form|
    PL2124966T3|2007-02-01|2016-01-29|Iams Europe B V|Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts|
    US8404275B2|2007-07-01|2013-03-26|Vitalis Llc|Combination tablet with chewable outer layer|
    US8110226B2|2007-07-20|2012-02-07|Mylan Pharmaceuticals Inc.|Drug formulations having inert sealed cores|
    US8486452B2|2007-07-20|2013-07-16|Mylan Pharmaceuticals Inc.|Stabilized tolterodine tartrate formulations|
    US9771199B2|2008-07-07|2017-09-26|Mars, Incorporated|Probiotic supplement, process for making, and packaging|
    US10104903B2|2009-07-31|2018-10-23|Mars, Incorporated|Animal food and its appearance|
    EP2770978B1|2011-10-28|2018-01-10|Vitalis LLC|Anti-flush compositions|
    CN104274408A|2013-07-10|2015-01-14|北京科信必成医药科技发展有限公司|Fusible coated immediate-release drug microgranule and preparation method thereof|
    CN107361392B|2017-07-26|2019-10-25|云南芯韵科技开发有限公司|A kind of three layers contain capsule with diuresis promoting function and preparation method thereof|
    法律状态:
    2006-11-28| CC| Certificate of correction|
    2007-03-07| AS| Assignment|Owner name: PHARMACIA & UPJOHN COMPANY LLC, MICHIGAN Free format text: CHANGE OF NAME;ASSIGNOR:PHARMACIA & UPJOHN COMPANY;REEL/FRAME:018961/0556 Effective date: 20040813 |
    2007-07-19| AS| Assignment|Owner name: MCNEIL-PPC, INC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PFIZER INC;PFIZER PRODUCTS INC;PFIZER JAPAN INC;AND OTHERS;REEL/FRAME:019573/0631 Effective date: 20070216 |
    2009-02-04| FPAY| Fee payment|Year of fee payment: 4 |
    2013-02-06| FPAY| Fee payment|Year of fee payment: 8 |
    2015-07-02| AS| Assignment|Owner name: JOHNSON & JOHNSON CONSUMER INC., NEW JERSEY Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:MCNEIL-PPC, INC.;JOHNSON & JOHNSON CONSUMER INC.;REEL/FRAME:036049/0254 Effective date: 20150623 |
    2017-04-14| REMI| Maintenance fee reminder mailed|
    2017-10-02| LAPS| Lapse for failure to pay maintenance fees|Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.) |
    2017-10-02| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2017-10-24| FP| Expired due to failure to pay maintenance fee|Effective date: 20170906 |
    优先权:
    申请号 | 申请日 | 专利标题
    US5721697P| true| 1997-08-29|1997-08-29||
    US09/139,449|US6228397B1|1997-08-29|1998-08-25|Pharmaceutical composition having two coating layers|
    US09/738,333|US6939560B2|1997-08-29|2000-12-15|Pharmaceutical composition having two coating layers|US09/738,333| US6939560B2|1997-08-29|2000-12-15|Pharmaceutical composition having two coating layers|
    [返回顶部]